Biopharma Diagnostics
  • Industries
  • Capabilities
  • Testing
  • FAQ
  • About Us
  • News
  • Contact
  • Search
Ethanol biomarker test features longer detection window
March 21, 2023

Mayo Clinic Laboratories has developed a new direct ethanol biomarker test for alcohol consumption that has a much longer detection window than existing urine tests for alcohol use.

Artificial intelligence paves way for earlier detection of gastrointestinal cancers
March 7, 2023

Mayo Clinic researchers are now using artificial intelligence (AI) systems to help increase polyp detection during colonoscopies and identify colorectal cancer at an early stage. Like facial recognition software that recognizes faces, this AI tool is being trained to recognize polyps. It works alongside the physician during a colonoscopy, scanning the video feed and drawing boxes around polyps that may otherwise have been overlooked due to their subtleness.

Identifying disease biomarkers with phage immunoprecipitation sequencing
January 24, 2023

Mayo Clinic’s Advanced Diagnostics Laboratory researchers are using phage immunoprecipitation sequencing to discover new serological biomarkers for autoimmune diseases.

Mayo Clinic Laboratories and Helix collaborate to provide comprehensive suite of laboratory services to biopharma customers
January 17, 2023

Together, Mayo Clinic Laboratories and Helix will provide biopharma customers with a full spectrum of testing capabilities and end-to-end laboratory testing support.

Noninvasive DNA testing via liquid biopsy
January 3, 2023

The MayoComplete Liquid Biopsy Panel offers a noninvasive alternative to traditional cell-based biopsies. This allow for faster turnaround time and the ability to perform molecular DNA testing in cancer patients where tumor tissue isn’t available.

Treating cancer with personalized vaccines
November 22, 2022

Mayo Clinic researchers are working on developing vaccines that would deliver therapeutic cancer treatment designed to target an individual’s unique tumor characteristics.

New e-guide identifies top qualities in a lab partner
November 15, 2022

BioPharma Diagnostics is offering a new e-guide titled “Finding the right laboratory partner: Top five qualities to support effective scientific research.”

Test in Focus: New FDA-approved test for Alzheimer’s disease
November 8, 2022

A new FDA-approved test offered by Mayo Clinic Laboratories is expanding testing options for patients with Alzheimer’s disease.

Optimizing leukemia treatment with enhanced genetic mutation detection
October 25, 2022

Mayo Clinic Laboratories has developed an assay that offers enhanced detection of the NPM1 genetic mutation that is present in about 30% of patients with acute myeloid leukemia, or AML.

Comprehensive assays for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
October 11, 2022

Mayo Clinic Laboratories offers a new test that builds upon the individual NF155 test to help physicians with early diagnosis and treatment optimization.

Patients face long waits for CAR T-cell therapy
October 4, 2022

Yi Lin, M.D., Ph.D., associate professor of medicine at Mayo Clinic and medical director for the Cellular Therapy Program, led a survey to investigate the scope of this problem, which has not been covered in literature thus far. The findings were published as an abstract at the recent annual meeting of the American Society of Clinical Oncology.

Inflammatory bowel disease
September 20, 2022

Inflammatory bowel disease (IBD) serology testing at Mayo Clinic Laboratories can help physicians distinguish between an ulcerative colitis diagnosis and a Crohn’s disease diagnosis. Melissa Snyder, Ph.D., explains in a “Test in Focus” episode of the “Answers From the Lab” podcast how the IBDP2 serology panel can make this important distinction after first-line testing has failed.

View MoreView Less
  • MAYO CLINIC
  • MAYO CLINIC LABORATORIES
  • JOBS
  • PRIVACY POLICY
  • Facebook
  • LinkedIn

Copyright © 1995-2023 Mayo Foundation For Medical Education And Research. All Rights Reserved

Manage Cookies
Loading...
Loading...